Transplant center directory

We are committed to excellence in patient care, research and education. Our multidisciplinary care team offers expertise and compassion. Our research team is at the forefront of improvements in conditioning regimens and alternative donor transplants including cord and mismatched donor transplant. We have several programs and features unique to our center, including the Adolescent and Young Adult Program (AYA), Transplant Optimization Program (TOP) for our older adult patients, and an outpatient stem cell transplant unit which allows us to offer outpatient transplant to eligible patients. We also perform haplo and mismatched unrelated donor transplant or cord transplant for patients who do not have a fully matched donor.

This center has been performing allogeneic transplants since 1985 and has been an NMDP/Be The Match transplant center since October 2001.

Comer Children's Hospital/University of Chicago Medicine

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 24 patients.

The actual 1-year survival of these patients is 83.3%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 68.9% and 96.5%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

University of Chicago Medicine

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 132 patients.

The actual 1-year survival of these patients is 72.3%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 67.2% and 81.6%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.